Lilly Halts India Obesity Awareness Campaign After Regulatory Scrutiny

By Intent.Health Team • May 11, 2026

What’s happening

Eli Lilly and Company paused an obesity awareness campaign in India after regulators questioned whether it indirectly promoted prescription obesity drugs.

What’s changing / Business impact

Regulators are increasing scrutiny on: obesity drug marketing and pharmaceutical advertising.
Drug companies face tighter controls on: awareness campaigns and indirect promotion strategies.

Why this matters

Obesity drugs are becoming one of the biggest pharmaceutical markets in the world.

This shows:

Companies are aggressively trying to expand obesity drug adoption globally.
Governments are becoming cautious about: over-promotion, public influence, and drug commercialization tactics.

YOUR NEXT MOVE

Bring your market into focus.

See how organizations, people, clinical activity and intent come together for your team.

Explore your use case ↗